Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.
In heart failure, sodium and water retention develop despite elevated plasma levels of atrial natriuretic peptide. Atrial natriuretic peptide is degraded in part by a neutral endopeptidase. Whether neutral endopeptidase inhibition improves sodium and water excretion in heart failure is unknown. We determined the effect of neutral endopeptidase inhibition on plasma levels of atrial natriuretic peptide and the renal response to acute volume expansion in rats with aortocaval shunts and in sham-operated controls. Acute endopeptidase inhibition with SQ 28,603 (30 mg/kg) elevated atrial natriuretic peptide plasma levels in both shunted rats (523 +/- 54 to 1258 +/- 330 pmol/L, P<.05) and controls (184 +/- 28 to 514 +/- 107 pmol/L, P<.05). Urinary cGMP excretion, which reflects renal action, increased in parallel. However, the diuretic and natriuretic responses to acute volume expansion were enhanced only in control rats and not in shunted rats. In contrast to the acute effects, chronic neutral endopeptidase inhibition with SCH 34826 (30 mg/kg twice daily) in shunted rats did not change atrial natriuretic peptide plasma levels or cGMP excretion. Nevertheless, the diuretic and natriuretic responses to acute volume load were increased by chronic endopeptidase inhibition in shunted rats (1789 +/- 154 to 2674 +/- 577 microL/80 min and 99 +/- 31 to 352 +/- 96 micromol/80 min, respectively; P<.05). Chronic endopeptidase inhibition attenuated the cardiac hypertrophic response to aortocaval shunt without changing arterial blood pressure. Our data show that the renal effects of neutral endopeptidase inhibition are not necessarily dependent on changes in atrial natriuretic peptide plasma levels but instead may be mediated by local inhibition of the neutral endopeptidase in the kidney. In addition, chronic endopeptidase inhibition may attenuate heart failure-induced cardiac hypertrophy independent of hemodynamic effects.
Willenbrock
R
R
Laboratory for Experimental Heart Failure LEH, Franz-Volhard-Klinik/Max-Delbrück-Centrum, Berlin, Germany.
Scheuermann
M
M
Höhnel
K
K
Luft
F C
FC
Dietz
R
R
D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000804:Angiotensin II / Q000097:blood; D000818:Animals; D001012:Aorta, Abdominal / Q000601:surgery; D001166:Arteriovenous Shunt, Surgical; D009320:Atrial Natriuretic Factor / Q000097:blood*; D006152:Cyclic GMP / Q000652:urine; D004231:Diuresis / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006333:Heart Failure / Q000378:metabolism*; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D015260:Neprilysin / Q000037:antagonists & inhibitors* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D012083:Renin / Q000097:blood; D014682:Vena Cava, Inferior / Q000601:surgery
D004791:Enzyme Inhibitors; C065359:SQ 28603; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D012083:Renin; D015260:Neprilysin; D006152:Cyclic GMP; D000409:Alanine